Suppr超能文献

非酒精性脂肪性肝炎中的抗氧化治疗

Antioxidant therapy in nonalcoholic steatohepatitis.

作者信息

Al-Busafi Said A, Bhat Mamatha, Wong Philip, Ghali Peter, Deschenes Marc

机构信息

Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Alkhoudh, Muscat 123, Oman ; Department of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada H3A 1A1.

出版信息

Hepat Res Treat. 2012;2012:947575. doi: 10.1155/2012/947575. Epub 2012 Nov 22.

Abstract

Nonalcoholic steatohepatitis (NASH) affects up to 3% of the North American population. It occurs as a manifestation of the insulin-resistant state and oxidative stress is thought to be a key component of its pathophysiology. Exercise and diet, which are the mainstay of therapy, are difficult to achieve and maintain with a disappointing long-term compliance record. There is growing literature on the potential for antioxidant therapy. The recent literature strongly suggests that vitamin E supplementation and other putative free radical scavengers and/or antioxidants are beneficial in improving biochemical and histological parameters in NASH.

摘要

非酒精性脂肪性肝炎(NASH)影响着高达3%的北美人口。它作为胰岛素抵抗状态的一种表现而出现,氧化应激被认为是其病理生理学的关键组成部分。运动和饮食是治疗的主要手段,但难以实现且维持,长期依从性记录令人失望。关于抗氧化治疗潜力的文献越来越多。最近的文献强烈表明,补充维生素E以及其他假定的自由基清除剂和/或抗氧化剂有助于改善NASH的生化和组织学参数。

相似文献

1
Antioxidant therapy in nonalcoholic steatohepatitis.
Hepat Res Treat. 2012;2012:947575. doi: 10.1155/2012/947575. Epub 2012 Nov 22.
2
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Clin Liver Dis. 2017 Nov;21(4):739-753. doi: 10.1016/j.cld.2017.06.010. Epub 2017 Jul 29.
3
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
6
Pharmacological agents for nonalcoholic steatohepatitis.
Hepatol Int. 2013 Dec;7 Suppl 2:833-41. doi: 10.1007/s12072-013-9482-8. Epub 2013 Nov 19.
7
Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.
BMC Pharmacol Toxicol. 2016 Apr 14;17:16. doi: 10.1186/s40360-016-0059-8.
8
The Role of Vitamin E in the Treatment of NAFLD.
Diseases. 2018 Sep 24;6(4):86. doi: 10.3390/diseases6040086.
9
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
Hepatology. 2007 Nov;46(5):1392-403. doi: 10.1002/hep.21874.
10
Vitamin E and nonalcoholic fatty liver disease.
Curr Opin Clin Nutr Metab Care. 2012 Nov;15(6):641-8. doi: 10.1097/MCO.0b013e328357f747.

引用本文的文献

1
Mechanism and therapeutic potential of liver injury induced by cholesterol-associated proteins.
Front Pharmacol. 2025 Mar 27;16:1572592. doi: 10.3389/fphar.2025.1572592. eCollection 2025.
4
Vitamin E and Metabolic Health: Relevance of Interactions with Other Micronutrients.
Antioxidants (Basel). 2022 Sep 9;11(9):1785. doi: 10.3390/antiox11091785.
6
7
Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
Cells. 2021 Dec 2;10(12):3401. doi: 10.3390/cells10123401.
9
Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma.
Biomedicines. 2021 Feb 12;9(2):184. doi: 10.3390/biomedicines9020184.
10
Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma.
Nutrients. 2020 May 28;12(6):1576. doi: 10.3390/nu12061576.

本文引用的文献

3
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis.
Free Radic Biol Med. 2012 Jan 1;52(1):59-69. doi: 10.1016/j.freeradbiomed.2011.10.003. Epub 2011 Oct 13.
5
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
Hepatol Res. 2012 Jan;42(1):1-14. doi: 10.1111/j.1872-034X.2011.00872.x. Epub 2011 Sep 15.
10
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验